AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21896611 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 111
Study 21896611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 111
Study 19011582 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) treatment for 1 hour once a day for 20 days over 4 weeks
Number of subjects: 57
Study 19011582 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy treatment (CPT) protocol for 1 hour once a day for 20 days over 4 weeks
Number of subjects: 57
Study 16918854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention designed to help families manage a child's asthma
Number of subjects: 3408
Study 15536845 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser curing (10 seconds, 250 mW)
Number of subjects: 45
Study 15536845 — intervention group
Group type: COMPARATOR
Intervention: Conventional visible light curing (40 seconds)
Number of subjects: 45
Study 15536845 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 45
Study 11747981 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (1 g orally daily for 14 days)
Number of subjects: 31
Study 11747981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 11747981 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone and Placebo
Number of subjects: 31
Study 9034837 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP
Number of subjects: 40
Study 9034837 — intervention group
Group type: COMPARATOR
Intervention: Hemodilution therapy
Number of subjects: 40
Study 8323420 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician prompting with diagnostic information and counseling directives
Number of subjects: 214
Study 8323420 — intervention group
Group type: COMPARATOR
Intervention: No physician prompting (control group)
Number of subjects: 214
Study 3084332 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory continuous enteral nutrition (CEN) at a rate of 35-45 kcal/kg/d (lipids: 35%, carbohydrates: 45%)
Number of subjects: 98
Study 3084332 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-ambulatory CEN
Number of subjects: 98
Study 31394939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) for 12 weeks
Number of subjects: 44
Study 31394939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) during exercise
Number of subjects: 44
Study 31394939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension (n=11)
Number of subjects: 44
Study 31394939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy (PEMF) in subjects with resting hypertension
Number of subjects: 44
Study 31394939 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 44
Study 30181075 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + phone call 48 hours after discharge
Number of subjects: 251
Study 30181075 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + text message 48 hours after discharge
Number of subjects: 251
Study 30181075 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual discharge)
Number of subjects: 251
Study 30181075 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 251
Study 27531316 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62
Study 27531316 — intervention group
Group type: EXPERIMENTAL
Intervention: Best time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62
Study 27531316 — intervention group
Group type: COMPARATOR
Intervention: No time goals for 5 Fundamentals of Laparoscopic Surgery (FLS) tasks
Number of subjects: 62
Study 25308211 — intervention group
Group type: EXPERIMENTAL
Intervention: Theracurmin (180 mg/day)
Number of subjects: 50
Study 25308211 — intervention group
Group type: EXPERIMENTAL
Intervention: Theracurmin
Number of subjects: 50
Study 25308211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22309202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level of Response-based (LRB) Group
Number of subjects: 64
Study 22309202 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-Art (SOTA) Group
Number of subjects: 64
Study 20383874 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NAC (1200 mg) plus saline hydration (Group 1, n=25)
Number of subjects: 45
Study 20383874 — intervention group
Group type: COMPARATOR
Intervention: Saline hydration (Group 2, n=20)
Number of subjects: 45
Study 20383874 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 45
Study 18757783 — intervention group
Group type: EXPERIMENTAL
Intervention: Odiparcil with aspirin (ASA)
Number of subjects: 0
Study 18757783 — intervention group
Group type: EXPERIMENTAL
Intervention: Odiparcil with enoxaparin
Number of subjects: 0
Study 18757783 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15502972 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 50 mg/day
Number of subjects: 55
Study 15502972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11916799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% with fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0
Study 11916799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625% with fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0
Study 11916799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.04% with epinephrine 1:600,000 and fentanyl 2 microg/mL at 10 mL/h
Number of subjects: 0
Study 11916799 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 9583771 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg)
Number of subjects: 15
Study 9583771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8559197 — intervention group
Group type: EXPERIMENTAL
Intervention: eberconazole cream 1% once daily (group A)
Number of subjects: 60
Study 8559197 — intervention group
Group type: EXPERIMENTAL
Intervention: eberconazole cream 1% twice daily (group B)
Number of subjects: 60
Study 8559197 — intervention group
Group type: EXPERIMENTAL
Intervention: eberconazole cream 2% once daily (group C)
Number of subjects: 60
Study 8559197 — intervention group
Group type: EXPERIMENTAL
Intervention: eberconazole cream 2% twice daily (group D)
Number of subjects: 60
Study 2507630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 81
Study 2507630 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 81
Study 2507630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 830880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 35
Study 830880 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (Control)
Number of subjects: 35
Study 31590688 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based family health history collection tool and decision support platform (MeTree)
Number of subjects: 0
Study 31590688 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (access to MeTree 12 months post-consent)
Number of subjects: 0
Study 28301292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse width modulated (PWM) red LED light (625 nm, 76 Hz, 23% Duty Cycle) applied for 2 minutes during surgery
Number of subjects: 263
Study 28301292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PWM red LED light treatment)
Number of subjects: 263
Study 25062900 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical training for 16 weeks
Number of subjects: 45
Study 25062900 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 23579103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5mg/mL
Number of subjects: 102
Study 23579103 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 10mg/mL
Number of subjects: 102
Study 21994354 — intervention group
Group type: COMPARATOR
Intervention: ACE527 (three-strain combination live attenuated vaccine) at doses of 10^10 and 10^11 total CFU
Number of subjects: 0
Study 21994354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19523014 — intervention group
Group type: COMPARATOR
Intervention: i.v. omeprazole (OME group, 40 mg i.v. infusion every 12 h for 3 days)
Number of subjects: 156
Study 19523014 — intervention group
Group type: EXPERIMENTAL
Intervention: oral rabeprazole (RAB group, 20 mg twice daily for 3 days)
Number of subjects: 156
Study 19523014 — intervention group
Group type: COMPARATOR
Intervention: i.v. omeprazole (OME group)
Number of subjects: 156
Study 19523014 — intervention group
Group type: EXPERIMENTAL
Intervention: oral rabeprazole (RAB group)
Number of subjects: 156
Study 16766333 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% shampoo
Number of subjects: 162
Study 16766333 — intervention group
Group type: COMPARATOR
Intervention: Tar blend 1% shampoo
Number of subjects: 162
Study 23570221 — intervention group
Group type: EXPERIMENTAL
Intervention: VitalPoll Telemedicine System (VTS)
Number of subjects: 0
Study 11688083 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 1 sugar (10 mg of iron/kg of sugar)
Number of subjects: 93
Study 11688083 — intervention group
Group type: EXPERIMENTAL
Intervention: Level 2 sugar (100 mg of iron/kg of sugar)
Number of subjects: 93
Study 11688083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (considering only anemic children)
Number of subjects: 93
Study 9716763 — intervention group
Group type: EXPERIMENTAL
Intervention: Five weekly practice sessions (Group A)
Number of subjects: 12
Study 9716763 — intervention group
Group type: COMPARATOR
Intervention: No practice (Group B)
Number of subjects: 12
Study 8288056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 102
Study 8288056 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 102
Study 8288056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 2605074 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (1 MAC end‐tidal concentration)
Number of subjects: 16
Study 2605074 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (control group)
Number of subjects: 16
Study 4394650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol administration
Number of subjects: 0
Study 4394650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol administration
Number of subjects: 0
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications
Number of subjects: 12899
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-related factors (gender, socioeconomic status, language spoken at home, lifestyle and comorbidities) and drug-related factors (total number and drug class)
Number of subjects: 12899
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in remote areas
Number of subjects: 12899
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Family income over 70,000 AUD/year
Number of subjects: 12899
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking other languages at home
Number of subjects: 12899
Study 31034700 — intervention group
Group type: EXPERIMENTAL
Intervention: Using cholinergic classes of medications
Number of subjects: 12899
Study 30922017 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-heating blanket (SHB)
Number of subjects: 86
Study 30922017 — intervention group
Group type: COMPARATOR
Intervention: Forced-air blanket (FAB)
Number of subjects: 86
Study 25618418 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholegrain diet (>80 g/day)
Number of subjects: 0
Study 25618418 — intervention group
Group type: COMPARATOR
Intervention: Refined grain diet (<16 g/day)
Number of subjects: 0
Study 25209550 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART initiation
Number of subjects: 400
Study 22176653 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ascorbic acid (vitamin C) for 4 weeks
Number of subjects: 53
Study 22176653 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 53
Study 20078871 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 56
Study 20078871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 56
Study 17071939 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 0.75 mg/m2, days 1-5, and carboplatin AUC 5, day 5 (arm A)
Number of subjects: 100
Study 17071939 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.25 mg/m2, days 1-3, and carboplatin AUC 5, day 3 (arm B)
Number of subjects: 100
Study 16291354 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and zinc supplementation (30 mg ferrous fumarate, 30 mg zinc oxide, both, or placebo daily for 6 months)
Number of subjects: 602
Study 16291354 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 602
Study 16291354 — intervention group
Group type: COMPARATOR
Intervention: Teacher ratings
Number of subjects: 602
Study 11835297 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low calorie diet (VLCD) program
Number of subjects: 128
Study 10404573 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent low back pain group (n = 40)
Number of subjects: 80
Study 10404573 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc degeneration at 15 years
Number of subjects: 80
Study 10404573 — intervention group
Group type: EXPERIMENTAL
Intervention: Disc protrusion and Scheuermann-type changes at 15 years
Number of subjects: 80
Study 10404573 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic control group (n = 40)
Number of subjects: 80
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 57
Study 8681312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2188023 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational curriculum focused on child development, family support, and pediatric follow-up
Number of subjects: 985
Study 2188023 — intervention group
Group type: COMPARATOR
Intervention: Only pediatric follow-up
Number of subjects: 985
Study 6997792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 150
Study 6997792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 150
Study 6997792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 6862582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12
Study 6862582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 12
Study 6862582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6862582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg) in hyperadrenergic patients
Number of subjects: 12
Study 31082512 — intervention group
Group type: COMPARATOR
Intervention: Standardised Chinese herbal medicine (CHM)
Number of subjects: 61
Study 31082512 — intervention group
Group type: COMPARATOR
Intervention: Individualised Chinese herbal medicine (CHM)
Number of subjects: 61
Study 31082512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30026335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 813
Study 30026335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 813
Study 30026335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 813
Study 26837479 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 118
Study 26837479 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise therapy
Number of subjects: 118
Study 24759256 — intervention group
Group type: EXPERIMENTAL
Intervention: Grains of paradise (GP) extract (30 mg/d) for 4 weeks
Number of subjects: 19
Study 24759256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23038982 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of dried barberry (600 mg daily for 4 weeks)
Number of subjects: 49
Study 23038982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20807094 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVBP
Number of subjects: 652
Study 20807094 — intervention group
Group type: COMPARATOR
Intervention: ECVBP
Number of subjects: 652
Study 20807094 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVBP (in patients with DLBCL)
Number of subjects: 652
Study 17984165 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 15067
Study 17984165 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin alone
Number of subjects: 15067
Study 15845130 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard assessments at age 3
Number of subjects: 26
Study 15845130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of non-verbal communicative acts from interactive play-based assessment at age 2
Number of subjects: 26
Study 15845130 — intervention group
Group type: COMPARATOR
Intervention: Standard assessments at age 2
Number of subjects: 26
Study 12456431 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 80
Study 12456431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 10495176 — intervention group
Group type: EXPERIMENTAL
Intervention: Water irrigation
Number of subjects: 20
Study 10495176 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 20
Study 8543208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-synchronised image acquisition using an electrocardiographic signal
Number of subjects: 25
Study 8543208 — intervention group
Group type: COMPARATOR
Intervention: Normal image acquisition
Number of subjects: 25
Study 8543208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-synchronised image acquisition
Number of subjects: 25
Study 1961959 — intervention group
Group type: COMPARATOR
Intervention: Thiopental, 4 mg/kg
Number of subjects: 40
Study 1961959 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg
Number of subjects: 40
Study 1961959 — intervention group
Group type: COMPARATOR
Intervention: Thiopental with N2O at 66%
Number of subjects: 40
Study 1961959 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 1961959 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 40
Study 1961959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 7026795 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in muscle relaxation
Number of subjects: 0
Study 7026795 — intervention group
Group type: COMPARATOR
Intervention: Information about sensations experienced during surgery
Number of subjects: 0
Study 31737175 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin with vitamin D and vitamin E (RealSIL 100D®) for six months
Number of subjects: 90
Study 31737175 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 90
Study 31737175 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybin with vitamin D and vitamin E (RealSIL 100D®) for six months in patients with concomitant metabolic syndrome
Number of subjects: 90
Study 27911295 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) with 5% albumin (Albutein®, Grifols)
Number of subjects: 42
Study 27911295 — intervention group
Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 42
Study 26019129 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 intermediate or poor metabolizer status
Number of subjects: 522
Study 26019129 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 extensive or ultrarapid metabolizer status
Number of subjects: 522
Study 26019129 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype-inferred metabolizer status
Number of subjects: 522
Study 23999502 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level and multi-component interventions
Number of subjects: 1700
Study 21876313 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 40
Study 21876313 — intervention group
Group type: COMPARATOR
Intervention: Low-dose MMF
Number of subjects: 40
Study 19616297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact dentin
Number of subjects: 70
Study 19616297 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared but unobturated canal
Number of subjects: 70
Study 19616297 — intervention group
Group type: EXPERIMENTAL
Intervention: Canal obturated with epoxy resin (AH Plus/gutta percha)
Number of subjects: 70
Study 19616297 — intervention group
Group type: EXPERIMENTAL
Intervention: Canal obturated with UDMA resin sealer (Resilon/RealSeal)
Number of subjects: 70
Study 19616297 — intervention group
Group type: COMPARATOR
Intervention: Wf perpendicular to tubule direction
Number of subjects: 70
Study 16920249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclogest 400mg
Number of subjects: 132
Study 16920249 — intervention group
Group type: COMPARATOR
Intervention: Endometrin 100mg
Number of subjects: 132
Study 15313807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital education plus tailored materials and telephone counseling
Number of subjects: 108
Study 15313807 — intervention group
Group type: COMPARATOR
Intervention: Hospital education alone
Number of subjects: 108
Study 15313807 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 108